VIDEO: New EMERALD trial results show promise in pretreated breast cancer subset
Click Here to Manage Email Alerts
In this video, Paolo Tarantino, MD, discusses findings from the EMERALD phase 3 trial presented at San Antonio Breast Cancer Symposium.
The study compared the use of elacestrant (Menarini Group/Stemline Therapeutics) monotherapy to a standard-of-care endocrine therapy in patients with ER-positive, HER2-negative metastatic breast cancer. The results presented at the meeting were an update to previously presented data, based on the duration of prior CDK4/6 inhibitors in patients with metastatic breast cancer.
“What we saw at San Antonio was that most of the benefit was observed in patients that had tumors with ESR1 mutations and patients that received prior CDK4/6 inhibitors for at least 1 year,” Tarantino, a clinical research fellow at Dana-Farber Cancer Institute and at Harvard Medical School, told Healio.
“I think this data really helped us to understand how to use elacestrant, in case in the future it became another treatment option in the clinic,” Tarantino said
Collapse
Read more about
Click Here to Manage Email Alerts